CoChat
Sign Up
Cited by 332Schizophrenia research and treatmentTreatment of Major DepressionMental Health and Psychiatry

The DOI matches its Crossref record; 116 of the 118 references it cites were found in a registry or an index.

Guidelines for the Pharmacotherapy of Schizophrenia in Adults

Open access
Remington, Gary, Addington, Donald, Honer, William, Ismail, Zahinoor, Raedler, Thomas, Teehan, Michael·2017·The Canadian Journal of Psychiatry
DOI 10.1177/0706743717720448PMC PMC5593252
Open this paper in CoChat — free accountOpen PDF

Abstract

Objective: The present guidelines address the pharmacotherapy of schizophrenia in adults across different stages, phases, and symptom domains. Method: Guidelines were developed using the ADAPTE process, which takes advantage of existing guidelines. Six guidelines were identified for adaptation, with recommendations extracted from each. For those specific to the pharmacotherapy of schizophrenia in adults, a working group selected between guidelines and recommendations to create an adapted guideline. Results: Recommendations can be categorized into 6 areas that include 1) first-episode schizophrenia, 2) acute exacerbation, 3) relapse prevention and maintenance treatment, 4) treatment-resistant schizophrenia, 5) clozapine-resistant schizophrenia, and 6) specific symptom domains. For each category, recommendations are made based on the available evidence, which is discussed and linked to other established guidelines. Conclusions: In most cases, evidence-based recommendations are made that can be used to guide current clinical treatment and decision making. Notably, however, there is a paucity of established evidence to guide treatment decision making in the case of clozapine-resistant schizophrenia, a subsample that represents a sizable proportion of those with schizophrenia.

Overview

Integrity signals

Registry

Crossref · 10.1177/0706743717720448

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 118 references

Research works printed but not linked: 12

  1. National Collaborating Centre for Mental Health, 2013, National Clinical Guideline Number, 155
  2. Agid O, 2006, J Psychiatry Neurosci, 31, 93
  3. Kane JM, 1996, J Clin Psychiatry, 57, 35
  4. Asenjo Lobos C, 2010, Cochrane Database Syst Rev, CD006633
  5. Rhoades HM, 1988, Psychopharmacol Bull, 24, 101
  6. Woerner MG, 1988, Psychopharmacol Bull, 24, 112
  7. Powney MJ, 2012, Cochrane Database Syst Rev, 11, CD009377
  8. Gillies D, 2013, Cochrane Database Syst Rev, 4, CD003079
  9. Volavka J, 2013, Psychiatr Danub, 25, 24
  10. Kane JM, 2003, J Clin Psychiatry, 64, 5
  11. Whitehead C, 2002, Cochrane Database Syst Rev, CD002305
  12. Cipriani A, 2011, BMJ Clin Evid, 1

Cited by

Sorted by citations

Items 201–300 of 332

Related

See all

Metadata

Authors
Remington, G., Addington, D., Honer, W., Ismail, Z., Raedler, T., & Teehan, M.
Affiliations
  • Centre for Addiction and Mental Health (CA)
  • University of Calgary (CA)
  • University of British Columbia (CA)
  • Dalhousie University (CA)
Corresponding author
Remington, Gary
ORCID
Venue
The Canadian Journal of Psychiatry
Publisher
SAGE Publications
Published
2017-07-13
Volume
62
Issue
9
Pages
604-616
ISSN
  • 0706-7437 (ISSN-L)
  • 1497-0015
DOI
10.1177/0706743717720448
PMC
PMC5593252
OpenAlex
W2737472140
Cited by
332
References
118
Citations by year
2026: 29 · 2025: 32 · 2024: 46 · 2023: 38 · 2022: 66 · 2021: 56 · 2020: 23 · 2019: 28 · 2018: 13 · 2017: 1
FWCI
14.59
Type
journal article
Language
en
Open access
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • The Canadian Journal of Psychiatry (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
Hotchkiss Brain Institute, University of Calgary
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
Keywords
schizophrenia, pharmacotherapy, adults, first-episode schizophrenia, acute exacerbation, relapse prevention, maintenance therapy, treatment-resistant schizophrenia, clozapine-resistant schizophrenia, antipsychotic drugs, symptom domains, evidence-based recommendations
MeSH terms
Adult, Canada, Humans, Schizophrenia, Antipsychotic Agents, Practice Guidelines as Topic, Evidence-Based Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review